Solberg R, Andresen JH, Escrig R, Vento M, Saugstad OD
Ch.2.2.2.1 (eds Picardo, M
Over time, this chronic immune activation may contribute to fatigue, cognitive changes, digestive disruption, respiratory symptoms, metabolic instability, and heightened inflammatory sensitivity
Because formal, large-scale Phase 3 clinical trials for Long COVID are still scaling up, researchers have relied heavily on massive patient-reported outcome surveys to see what is working in real-world clinical settings
Taking this into consideration, we postulate that in our treatment AITC also led to a decrease of glutathione levels
Dauber A, Muoz-Calvo MT, Barrios V, Domen HM, Kloverpris S, Serra-Juh C, Desikan V, Pozo J, Muzumdar R, Martos-Moreno G, Hawkins F, Jasper HG, Conover CA, Frystyk J, Yakar S, Hwa V, Chowen JA, Oxvig C, Rosenfeld RG, Prez-Jurado LA, Argente J